John Jagerson and Wade Hansen

By John Jagerson and Wade Hansen Sep 23, 2016

AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.

By John Jagerson and Wade Hansen Sep 16, 2016

The recovery isn't as bullish as the S&P 500's, but the China economy isn’t showing signs of the bubbly fervor of 2015.

By John Jagerson and Wade Hansen Sep 16, 2016

The rising U.S. dollar (USD) is also likely to have a negative impact on iShares Emerging Markets ETF (NYSEARCA:EEM).

By John Jagerson and Wade Hansen Sep 12, 2016

While September is the most volatile month in the market, things start perking up in fall. Expect outperformance from these five stocks to buy.

By John Jagerson and Wade Hansen Sep 9, 2016

Despite the flat trading, technicals suggest the markets should break out soon, but it's tough to tell which way.

Recent Articles